{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:39:36Z","timestamp":1791725976688,"version":"4.3.4"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00228-025-03849-z","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T08:14:27Z","timestamp":1747901667000},"page":"1081-1096","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Signal detection of ferric carboxymaltose-induced serious adverse events: disproportionality analysis of FAERS and VigiBase data and systematic review of case reports"],"prefix":"10.1007","volume":"81","author":[{"given":"Reddikumar Reddy","family":"Galigutta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Rathod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. N.","family":"Hasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. S.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7480-8761","authenticated-orcid":false,"given":"Krishna","family":"Undela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"3849_CR1","unstructured":"Worldwide prevalence of anaemia 1993\u20132005\u202f: WHO global database on anaemia. \/ Edited by Bruno de Benoist, Erin McLean, Ines Egli and Mary Cogswell. https:\/\/apps.who.int\/iris\/handle\/10665\/43894. Accessed 19 Jul 2023"},{"key":"3849_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2318-8-1","volume":"8","author":"H Gaskell","year":"2008","unstructured":"Gaskell H, Derry S, Andrew Moore R, McQuay HJ (2008) Prevalence of anaemia in older persons: systematic review. BMC Geriatr 8:1. https:\/\/doi.org\/10.1186\/1471-2318-8-1","journal-title":"BMC Geriatr"},{"key":"3849_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12325-020-01524-6","volume":"38","author":"RM Hanna","year":"2021","unstructured":"Hanna RM, Streja E, Kalantar-Zadeh K (2021) Burden of anemia in chronic kidney disease: beyond erythropoietin. Adv Ther 38:52\u201375. https:\/\/doi.org\/10.1007\/s12325-020-01524-6","journal-title":"Adv Ther"},{"key":"3849_CR4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.5581\/1516-8484.20110123","volume":"33","author":"RD Can\u00e7ado","year":"2011","unstructured":"Can\u00e7ado RD, Mu\u00f1oz M (2011) Intravenous iron therapy: how far have we come? Rev Bras Hematol Hemoter 33:461\u2013469. https:\/\/doi.org\/10.5581\/1516-8484.20110123","journal-title":"Rev Bras Hematol Hemoter"},{"key":"3849_CR5","doi-asserted-by":"publisher","first-page":"4666","DOI":"10.3748\/WJG.15.4666","volume":"15","author":"M Mu\u00f1oz","year":"2009","unstructured":"Mu\u00f1oz M, G\u00f3mez-Ram\u00edrez S, Garc\u00eda-Erce JA (2009) Intravenous iron in inflammatory bowel disease. World J Gastroenterol 15:4666\u20134674. https:\/\/doi.org\/10.3748\/WJG.15.4666","journal-title":"World J Gastroenterol"},{"key":"3849_CR6","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1080\/00365520510023198","volume":"40","author":"K Erichsen","year":"2005","unstructured":"Erichsen K, Ulvik RJ, Nysaeter G et al (2005) Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol 40:1058\u20131065. https:\/\/doi.org\/10.1080\/00365520510023198","journal-title":"Scand J Gastroenterol"},{"key":"3849_CR7","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1111\/J.1572-0241.2001.04094.X","volume":"96","author":"C Gasche","year":"2001","unstructured":"Gasche C, Waldhoer T, Feichtenschlager T et al (2001) Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol 96:2382\u20132387. https:\/\/doi.org\/10.1111\/J.1572-0241.2001.04094.X","journal-title":"Am J Gastroenterol"},{"key":"3849_CR8","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1080\/00365520902839667","volume":"44","author":"S Lindgren","year":"2009","unstructured":"Lindgren S, Wikman O, Befrits R et al (2009) Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol 44:838\u2013845. https:\/\/doi.org\/10.1080\/00365520902839667","journal-title":"Scand J Gastroenterol"},{"key":"3849_CR9","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1111\/J.1572-0241.2005.00250.X","volume":"100","author":"O Schr\u00f6der","year":"2005","unstructured":"Schr\u00f6der O, Mickisch O, Seidler U et al (2005) Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease\u2013a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 100:2503\u20132509. https:\/\/doi.org\/10.1111\/J.1572-0241.2005.00250.X","journal-title":"Am J Gastroenterol"},{"key":"3849_CR10","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1001\/JAMA.2015.15572","volume":"314","author":"C Wang","year":"2015","unstructured":"Wang C, Graham DJ, Kane RC et al (2015) Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA 314:2062\u20132068. https:\/\/doi.org\/10.1001\/JAMA.2015.15572","journal-title":"JAMA"},{"key":"3849_CR11","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3324\/HAEMATOL.2014.111492","volume":"99","author":"D Rampton","year":"2014","unstructured":"Rampton D, Folkersen J, Fishbane S et al (2014) Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica 99:1671\u20131676. https:\/\/doi.org\/10.3324\/HAEMATOL.2014.111492","journal-title":"Haematologica"},{"key":"3849_CR12","doi-asserted-by":"publisher","first-page":"739","DOI":"10.2165\/00003495-200969060-00007","volume":"69","author":"KA Lyseng-Williamson","year":"2009","unstructured":"Lyseng-Williamson KA, Keating GM (2009) Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs 69:739\u2013756. https:\/\/doi.org\/10.2165\/00003495-200969060-00007","journal-title":"Drugs"},{"key":"3849_CR13","doi-asserted-by":"publisher","unstructured":"Jose A, Mahey R, Sharma JB, et al (2019) Comparison of ferric carboxymaltose and iron sucrose complex for treatment of iron deficiency anemia in pregnancy\u2014randomised controlled trial. BMC Pregnancy Childbirth 19. https:\/\/doi.org\/10.1186\/S12884-019-2200-3","DOI":"10.1186\/S12884-019-2200-3"},{"key":"3849_CR14","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/NDT\/GFU201","volume":"29","author":"IC Macdougall","year":"2014","unstructured":"Macdougall IC, Bock AH, Carrera F et al (2014) FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transpl 29:2075\u20132084. https:\/\/doi.org\/10.1093\/NDT\/GFU201","journal-title":"Nephrol Dial Transpl"},{"key":"3849_CR15","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","volume":"396","author":"P Ponikowski","year":"2020","unstructured":"Ponikowski P, Kirwan B-A, Anker SD et al (2020) Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 396:1895\u20131904. https:\/\/doi.org\/10.1016\/S0140-6736(20)32339-4","journal-title":"Lancet"},{"key":"3849_CR16","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1002\/AJH.26376","volume":"96","author":"T Makharadze","year":"2021","unstructured":"Makharadze T, Boccia R, Krupa A et al (2021) Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: a randomized, placebo-controlled study (IRON-CLAD). Am J Hematol 96:1639\u20131646. https:\/\/doi.org\/10.1002\/AJH.26376","journal-title":"Am J Hematol"},{"key":"3849_CR17","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2450\/2021.0157-21","volume":"20","author":"MJ Laso-Morales","year":"2022","unstructured":"Laso-Morales MJ, Vives R, Bisbe E et al (2022) Single-dose intravenous ferric carboxymaltose infusion versus multiple fractionated doses of intravenous iron sucrose in the treatment of post-operative anaemia in colorectal cancer patients: a randomised controlled trial. Blood Transfus 20:310\u2013318. https:\/\/doi.org\/10.2450\/2021.0157-21","journal-title":"Blood Transfus"},{"key":"3849_CR18","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1016\/S2352-3026(16)30078-3","volume":"3","author":"AA Khalafallah","year":"2016","unstructured":"Khalafallah AA, Yan C, Al-Badri R et al (2016) Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial. Lancet Haematol 3:e415\u2013e425. https:\/\/doi.org\/10.1016\/S2352-3026(16)30078-3","journal-title":"Lancet Haematol"},{"key":"3849_CR19","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/NDT\/GFT251","volume":"29","author":"JE Onken","year":"2014","unstructured":"Onken JE, Bregman DB, Harrington RA et al (2014) Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transpl 29:833\u2013842. https:\/\/doi.org\/10.1093\/NDT\/GFT251","journal-title":"Nephrol Dial Transpl"},{"key":"3849_CR20","doi-asserted-by":"publisher","unstructured":"Moore RA, Gaskell H, Rose P, Allan J (2011) Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord 11. https:\/\/doi.org\/10.1186\/1471-2326-11-4","DOI":"10.1186\/1471-2326-11-4"},{"key":"3849_CR21","unstructured":"Ferinject (ferric carboxymaltose)\u2014Summary of product characteristics (SmPC)\u2014(emc). https:\/\/www.medicines.org.uk\/emc\/product\/5910\/smpc. Accessed 20 Nov 2023"},{"key":"3849_CR22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/S40265-018-0885-7","volume":"78","author":"LJ Scott","year":"2018","unstructured":"Scott LJ (2018) Ferric carboxymaltose: a review in iron deficiency. Drugs 78:479\u2013493. https:\/\/doi.org\/10.1007\/S40265-018-0885-7","journal-title":"Drugs"},{"key":"3849_CR23","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/J.BJHH.2015.08.012","volume":"37","author":"JR Friedrisch","year":"2015","unstructured":"Friedrisch JR, Can\u00e7ado RD (2015) Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia. Rev Bras Hematol Hemoter 37:400\u2013405. https:\/\/doi.org\/10.1016\/J.BJHH.2015.08.012","journal-title":"Rev Bras Hematol Hemoter"},{"key":"3849_CR24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/S40264-018-0769-5","volume":"42","author":"B Ehlken","year":"2019","unstructured":"Ehlken B, Nathell L, Gohlke A et al (2019) Evaluation of the reported rates of severe hypersensitivity reactions associated with ferric carboxymaltose and iron (III) isomaltoside 1000 in Europe based on data from EudraVigilance and VigiBase\u2122 between 2014 and 2017. Drug Saf 42:463\u2013471. https:\/\/doi.org\/10.1007\/S40264-018-0769-5","journal-title":"Drug Saf"},{"key":"3849_CR25","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/BCP.13805","volume":"85","author":"MB Mulder","year":"2019","unstructured":"Mulder MB, van den Hoek HL, Birnie E et al (2019) Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer\u00ae) versus ferric carboxy-maltose (Ferinject\u00ae). A single center, cohort study. Br J Clin Pharmacol 85:385\u2013392. https:\/\/doi.org\/10.1111\/BCP.13805","journal-title":"Br J Clin Pharmacol"},{"key":"3849_CR26","doi-asserted-by":"publisher","unstructured":"Toblli JE, Cao G, Angerosa M (2015) The induction of oxidative\/nitrosative stress, inflammation, and apoptosis by a ferric carboxymaltose copy compared to iron sucrose in a non-clinical model. J Clin Diagn Res 9:FF08-FF12. https:\/\/doi.org\/10.7860\/JCDR\/2015\/14266.6992","DOI":"10.7860\/JCDR\/2015\/14266.6992"},{"key":"3849_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/EJHF.823","volume":"20","author":"SD Anker","year":"2018","unstructured":"Anker SD, Kirwan BA, van Veldhuisen DJ et al (2018) Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail 20:125\u2013133. https:\/\/doi.org\/10.1002\/EJHF.823","journal-title":"Eur J Heart Fail"},{"key":"3849_CR28","doi-asserted-by":"publisher","unstructured":"Arica AM, Kumral Z, Gelal A, Akdeniz B (2020) Fatal anaphylactic reaction due to ferric carboxymaltose: a case report. Anatol J Cardiol 24:115\u2013117. https:\/\/doi.org\/10.14744\/AnatolJCardiol.2020.38996","DOI":"10.14744\/AnatolJCardiol.2020.38996"},{"key":"3849_CR29","unstructured":"FDA recalls Orofer FCM after Saifee patient\u2019s death | Mumbai news\u2014Hindustan Times. https:\/\/www.hindustantimes.com\/cities\/mumbai-news\/fda-recalls-orofer-fcm-after-saifee-patient-s-death-101669229583763.html. Accessed 20 Nov 2023"},{"key":"3849_CR30","unstructured":"What is a Serious Adverse Event? U.S. Food & Drug Administration. https:\/\/www.fda.gov\/safety\/reporting-seriousproblems-fda\/what-serious-adverse-event. Accessed 14 May 2025"},{"key":"3849_CR31","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.psychres.2018.09.014","volume":"270","author":"LHM Arias","year":"2018","unstructured":"Arias LHM, Fadrique RS, Garc\u00eda SP et al (2018) Antipsychotics and cardiovascular risk: a case\/non-case study. Psychiatry Res 270:341\u2013347. https:\/\/doi.org\/10.1016\/j.psychres.2018.09.014","journal-title":"Psychiatry Res"},{"key":"3849_CR32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/pds.848","volume":"12","author":"N Moore","year":"2003","unstructured":"Moore N, Hall G, Sturkenboom M et al (2003) Biases affecting the proportional reporting ratio (PRR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf 12:271\u2013281. https:\/\/doi.org\/10.1002\/pds.848","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3849_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2021.113168","volume":"404","author":"D Cepaityte","year":"2021","unstructured":"Cepaityte D, Siafis S, Papazisis G (2021) Safety of antipsychotic drugs: a systematic review of disproportionality analysis studies. Behav Brain Res 404:113168. https:\/\/doi.org\/10.1016\/j.bbr.2021.113168","journal-title":"Behav Brain Res"},{"key":"3849_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/schbul\/sbz093","volume":"46","author":"J De Leon","year":"2020","unstructured":"De Leon J, Sanz EJ, De las Cuevas C (2020) Data from the World Health Organization\u2019s Pharmacovigilance database supports the prominent role of pneumonia in mortality associated with clozapine adverse drug reactions. Schizophr Bull 46:1\u20133. https:\/\/doi.org\/10.1093\/schbul\/sbz093","journal-title":"Schizophr Bull"},{"key":"3849_CR35","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y (2013) Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci 10:796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048","journal-title":"Int J Med Sci"},{"key":"3849_CR36","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"J-L Montastruc","year":"2011","unstructured":"Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M (2011) Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 72:905\u2013908. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04037.x","journal-title":"Br J Clin Pharmacol"},{"key":"3849_CR37","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/CLEP.S365513","volume":"14","author":"Y Shu","year":"2022","unstructured":"Shu Y, He X, Liu Y et al (2022) A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system. Clin Epidemiol 14:789\u2013802. https:\/\/doi.org\/10.2147\/CLEP.S365513","journal-title":"Clin Epidemiol"},{"key":"3849_CR38","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.2147\/PPA.S495254","volume":"18","author":"C De las Cuevas","year":"2024","unstructured":"De las Cuevas C, Sanz EJ, de Leon J (2024) Pharmacovigilance in action: utilizing VigiBase data to improve clozapine safety. Patient Prefer Adherence 18:2261\u20132280. https:\/\/doi.org\/10.2147\/PPA.S495254","journal-title":"Patient Prefer Adherence"},{"key":"3849_CR39","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/14740338.2023.2284992","volume":"23","author":"A Muhammed","year":"2024","unstructured":"Muhammed A, Thomas C, Kalaiselvan V, Undela K (2024) Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials. Expert Opin Drug Saf 23:731\u2013742. https:\/\/doi.org\/10.1080\/14740338.2023.2284992","journal-title":"Expert Opin Drug Saf"},{"key":"3849_CR40","doi-asserted-by":"crossref","unstructured":"Undela K, Thomas C (2025) Disproportionality methods for signal detection in pharmacovigilance. In: Signal Analysis in Pharmacovigilance. CRC Press, pp 124\u2013134","DOI":"10.1201\/9781032629940-8"},{"key":"3849_CR41","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s11096-022-01476-7","volume":"44","author":"H Palapra","year":"2022","unstructured":"Palapra H, Viswam SK, Kalaiselvan V, Undela K (2022) SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports. Int J Clin Pharm 44:1425\u20131433. https:\/\/doi.org\/10.1007\/s11096-022-01476-7","journal-title":"Int J Clin Pharm"},{"key":"3849_CR42","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","volume":"23","author":"MH Murad","year":"2018","unstructured":"Murad MH, Sultan S, Haffar S, Bazerbachi F (2018) Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med 23:60\u201363. https:\/\/doi.org\/10.1136\/bmjebm-2017-110853","journal-title":"BMJ Evid Based Med"},{"key":"3849_CR43","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1093\/rheumatology\/kez627","volume":"59","author":"R Amarnani","year":"2020","unstructured":"Amarnani R, Travis S, Javaid MK (2020) Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia. Rheumatology 59:2166\u20132168. https:\/\/doi.org\/10.1093\/rheumatology\/kez627","journal-title":"Rheumatology"},{"key":"3849_CR44","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ando.2020.04.008","volume":"81","author":"S Rom\u00e1n-Gimeno","year":"2020","unstructured":"Rom\u00e1n-Gimeno S, Ortez-Toro JJ, Peteiro-Miranda CM et al (2020) Case report: rare cause of severe hypophosphatemia. Ann Endocrinol (Paris) 81:125\u2013126. https:\/\/doi.org\/10.1016\/j.ando.2020.04.008","journal-title":"Ann Endocrinol (Paris)"},{"key":"3849_CR45","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/S12288-018-1035-9","volume":"35","author":"S Vikrant","year":"2019","unstructured":"Vikrant S, Jaryal A (2019) Successful administration of iron sucrose in a patient with an anaphylactic reaction to ferric carboxymaltose. Indian J Hematol Blood Transfus 35:199\u2013200. https:\/\/doi.org\/10.1007\/S12288-018-1035-9","journal-title":"Indian J Hematol Blood Transfus"},{"key":"3849_CR46","doi-asserted-by":"publisher","unstructured":"Moreaux S, Hammoud R, Beauvillain C, et al (2023) Severe anaphylactic reaction to ferric carboxymaltose with positive skin and basophil activation tests. J Investig Allergol Clin Immunol 33:306\u2013309. https:\/\/doi.org\/10.18176\/JIACI.0870","DOI":"10.18176\/JIACI.0870"},{"key":"3849_CR47","first-page":"49","volume":"72","author":"AHJBJ Blazevic","year":"2014","unstructured":"Blazevic AHJBJ (2014) Severe hypophosphataemia after intravenous iron administration. Neth J Med 72:49\u201353","journal-title":"Neth J Med"},{"key":"3849_CR48","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/JGH3.12150","volume":"3","author":"W Fang","year":"2019","unstructured":"Fang W, McMahon LP, Bloom S, Garg M (2019) Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose. JGH Open 3:438\u2013440. https:\/\/doi.org\/10.1002\/JGH3.12150","journal-title":"JGH Open"},{"key":"3849_CR49","doi-asserted-by":"publisher","unstructured":"Thanusubramanian H, Patil N, Shenoy S, et al (2014) Adverse reactions of ferric carboxymaltose. J Clin Diagn Res 8:HD01\u2013HD02. https:\/\/doi.org\/10.7860\/JCDR\/2014\/9499.5015","DOI":"10.7860\/JCDR\/2014\/9499.5015"},{"key":"3849_CR50","doi-asserted-by":"publisher","unstructured":"Sam\u00f5es B, Silva B, Martins A, et al (2023) Hypophosphatemic osteomalacia induced by intravenous iron therapy: a case report. Joint Bone Spine 90:. https:\/\/doi.org\/10.1016\/j.jbspin.2023.105586","DOI":"10.1016\/j.jbspin.2023.105586"},{"key":"3849_CR51","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1053\/j.gastro.2016.09.050","volume":"152","author":"B Schaefer","year":"2017","unstructured":"Schaefer B, Glodny B, Zoller H (2017) Blood and bone loser. Gastroenterology 152:e5\u2013e6. https:\/\/doi.org\/10.1053\/j.gastro.2016.09.050","journal-title":"Gastroenterology"},{"key":"3849_CR52","doi-asserted-by":"publisher","unstructured":"Klein K, Asaad S, Econs M, Rubin JE (2018) Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration. BMJ Case Rep 2018. https:\/\/doi.org\/10.1136\/bcr-2017-222851","DOI":"10.1136\/bcr-2017-222851"},{"key":"3849_CR53","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"3849_CR54","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/S11096-023-01548-2","volume":"45","author":"NA Kennedy","year":"2023","unstructured":"Kennedy NA, Achebe MM, Biggar P et al (2023) A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose. Int J Clin Pharm 45:604\u2013612. https:\/\/doi.org\/10.1007\/S11096-023-01548-2","journal-title":"Int J Clin Pharm"},{"key":"3849_CR55","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/BCP.13189","volume":"83","author":"P Bager","year":"2017","unstructured":"Bager P, Hvas CL, Dahlerup JF (2017) Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions. Br J Clin Pharmacol 83:1118\u20131125. https:\/\/doi.org\/10.1111\/BCP.13189","journal-title":"Br J Clin Pharmacol"},{"key":"3849_CR56","doi-asserted-by":"publisher","first-page":"656","DOI":"10.7326\/M21-4009","volume":"175","author":"CV Dave","year":"2022","unstructured":"Dave CV, Brittenham GM, Carson JL, Setoguchi S (2022) Risks for anaphylaxis with intravenous iron formulations: a retrospective cohort study. Ann Intern Med 175:656\u2013664. https:\/\/doi.org\/10.7326\/M21-4009","journal-title":"Ann Intern Med"},{"key":"3849_CR57","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/JBMR.1923","volume":"28","author":"M Wolf","year":"2013","unstructured":"Wolf M, Koch TA, Bregman DB (2013) Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 28:1793\u20131803. https:\/\/doi.org\/10.1002\/JBMR.1923","journal-title":"J Bone Miner Res"},{"key":"3849_CR58","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/AJH.25060","volume":"93","author":"NF Adkinson","year":"2018","unstructured":"Adkinson NF, Strauss WE, Macdougall IC et al (2018) Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: a randomized trial. Am J Hematol 93:683\u2013690. https:\/\/doi.org\/10.1002\/AJH.25060","journal-title":"Am J Hematol"},{"key":"3849_CR59","unstructured":"Ferric carboxymaltose (Ferinject\u25bc): risk of symptomatic hypophosphataemia leading to osteomalacia and fractures\u2014GOV.UK. https:\/\/www.gov.uk\/drug-safety-update\/ferric-carboxymaltose-ferinject-risk-of-symptomatic-hypophosphataemia-leading-to-osteomalacia-and-fractures. Accessed 22 Apr 2024"},{"key":"3849_CR60","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1177\/147323001204000105","volume":"40","author":"Y Liu","year":"2012","unstructured":"Liu Y, Yang YM, Zhu J et al (2012) Anaemia and prognosis in acute coronary syndromes: a systematic review and meta-analysis. J Int Med Res 40:43\u201355. https:\/\/doi.org\/10.1177\/147323001204000105","journal-title":"J Int Med Res"},{"key":"3849_CR61","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1210\/jc.2008-2396","volume":"94","author":"BJ Schouten","year":"2009","unstructured":"Schouten BJ, Hunt PJ, Livesey JH et al (2009) FGF23 Elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab 94:2332\u20132337. https:\/\/doi.org\/10.1210\/jc.2008-2396","journal-title":"J Clin Endocrinol Metab"},{"key":"3849_CR62","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/BF01496662","volume":"61","author":"M Okada","year":"1983","unstructured":"Okada M, Imamura K, Iida M et al (1983) Hypophosphatemia induced by intravenous administration of saccharated iron oxide. Klin Wochenschr 61:99\u2013102. https:\/\/doi.org\/10.1007\/BF01496662","journal-title":"Klin Wochenschr"},{"key":"3849_CR63","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","volume":"43","author":"O Caster","year":"2020","unstructured":"Caster O, Aoki Y, Gattepaille LM, Grundmark B (2020) Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations. Drug Saf 43:479\u2013487","journal-title":"Drug Saf"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03849-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03849-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03849-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T06:12:46Z","timestamp":1749535966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03849-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3849"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03849-z","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"6 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}